| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $94M | ||
| $82M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Over the last 12 months, insiders at Avenue Therapeutics, Inc. have bought $0 and sold $0 worth of Avenue Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avenue Therapeutics, Inc. have bought $187,842 and sold $774,556 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 497 shares for transaction amount of $1,243 was made by KRANZLER JAY D (director) on 2024‑09‑30.
| 2024-12-02 | Sale | Herskowitz Neil | director | 23 0.0012% | $2.00 | $46 | -63.13% | |
| 2024-11-05 | Sale | KRANZLER JAY D | director | 61 0.0043% | $2.24 | $137 | -67.78% | |
| 2024-09-30 | KRANZLER JAY D | director | 497 0.037% | $2.50 | $1,243 | -67.87% | ||
| 2024-09-27 | KRANZLER JAY D | director | 3 0.0002% | $2.40 | $7 | -68.12% | ||
| 2023-12-11 | Sale | Davidow Robert L | 10 percent owner | 617,000 4.9094% | $0.14 | $86,560 | -64.66% | |
| 2023-09-08 | Fortress Biotech, Inc. | 10 percent owner | 418,410 4.9086% | $0.72 | $301,255 | -80.60% | ||
| 2023-09-08 | ROSENWALD LINDSAY A MD | director | 348,675 4.0905% | $0.72 | $251,046 | -80.60% | ||
| 2022-10-11 | Sale | InvaGen Pharmaceuticals, Inc. | director | 388,888 48.3396% | $7.71 | $3M | -59.86% | |
| 2021-09-15 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 7,160 0.042% | $1.62 | $11,599 | -69.05% | |
| 2021-05-06 | Herskowitz Neil | director | 2,500 0.0142% | $3.99 | $9,975 | -68.56% | ||
| 2020-08-20 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 3,840 0.0235% | $12.13 | $46,579 | -60.88% | |
| 2020-03-10 | Vazzano Joseph Walter | Chief Financial Officer | 1,889 0.0115% | $7.94 | $14,999 | +12.63% | ||
| 2020-03-09 | Vazzano Joseph Walter | Chief Financial Officer | 1,500 0.0093% | $7.99 | $11,983 | +13.49% | ||
| 2020-02-27 | Herskowitz Neil | director | 2,400 0.0139% | $8.20 | $19,680 | +3.72% | ||
| 2020-02-26 | Herskowitz Neil | director | 161 0.001% | $8.73 | $1,406 | +0.45% | ||
| 2020-02-25 | Herskowitz Neil | director | 10,000 0.0629% | $9.31 | $93,100 | -0.89% | ||
| 2020-02-25 | Vazzano Joseph Walter | Chief Financial Officer | 1,200 0.0074% | $9.09 | $10,908 | -0.89% | ||
| 2019-09-12 | Ingram Elizabeth Garrett | director | 16,000 0.0982% | $6.27 | $100,320 | +46.39% | ||
| 2019-08-09 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 2,375 0.0138% | $5.56 | $13,205 | +49.32% | |
| 2019-08-08 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 2,313 0.0141% | $5.62 | $12,999 | +55.35% |
| Fortress Biotech, Inc. | 10 percent owner | 1032390 32.4288% | $650,405.70 | 1 | 0 | <0.0001% |
| ROSENWALD LINDSAY A MD | director | 354318 11.1296% | $223,220.34 | 11 | 0 | <0.0001% |
| Paley Jeffrey | director | 79663 2.5023% | $50,187.69 | 2 | 0 | |
| Vazzano Joseph Walter | Chief Financial Officer | 65252 2.0497% | $41,108.76 | 3 | 4 | |
| Davidow Robert L | 10 percent owner | 22000 0.6911% | $13,860.00 | 0 | 1 | |
| Ingram Elizabeth Garrett | director | 16000 0.5026% | $10,080.00 | 1 | 0 | |
| KRANZLER JAY D | director | 559 0.0176% | $352.17 | 2 | 1 | <0.0001% |
| Herskowitz Neil | director | 97 0.003% | $61.11 | 18 | 1 | |
| InvaGen Pharmaceuticals, Inc. | director | 0 0% | $0 | 0 | 1 |
$1,138,733 | 28 | -4.94% | $3.57M | |
$547,862 | 19 | -29.82% | $3.48M | |
$337,688 | 19 | -33.30% | $3.69M | |
$138,573 | 16 | -25.71% | $4.2M | |
$8,079,884 | 14 | -43.20% | $2.62M | |
$389,864 | 11 | 12.52% | $4.81M | |
$105,917 | 11 | -28.06% | $2.87M | |
$18,269 | 10 | -21.15% | $3.12M | |
$90,087 | 9 | 20.06% | $3.74M | |
$77,559 | 8 | -64.02% | $1.7M | |
$245,000 | 7 | -62.00% | $4.64M | |
$70,828 | 6 | -57.96% | $2.33M | |
Avenue Therapeutics, Inc. (ATXI) | $553,551 | 4 | -74.30% | $2.38M |
$726,438 | 4 | -72.85% | $2.42M | |
$149,778 | 4 | -45.16% | $5.48M | |
$1,049,630 | 1 | -74.91% | $1.42M | |
$19,863 | 1 | 144.27% | $917,684.00 | |
$37,000 | 1 | 79.42% | $3.46M | |
$23,454 | 1 | -99.16% | $16,997.00 |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |